
zzso zzso are currently in clinical and zzso development for the treatment of various zzso Designed to direct and enhance the body's immune response to specific tumors, zzso zzso consist of a targeting domain (typically an zzso zzso that binds to a tumor zzso linked to a triggering arm that is specific for a zzso zzso capable of zzso a zzso or zzso response by zzso natural killer cells, zzso or other zzso zzso Recent animal studies have confirmed the therapeutic potential of zzso zzso however, results from clinical trials so far have been less promising and have revealed clear limitations of these zzso such as zzso and severe side effects caused by mass release of inflammatory zzso A second generation of zzso zzso zzso zzso zzso and zzso zzso has now been produced by using DNA zzso technology; these may theoretically improve tumor targeting and minimize side effects, eventually replacing the full-length zzso zzso Over the next few years, several zzso zzso zzso are expected to enter clinical trials and ultimately emerge as new pharmaceutical zzso This review briefly summarizes major trends in the development of zzso zzso for tumor therapy, and describes a rationale for the generation of novel zzso zzso 

